FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts

Delcath Systems Inc. (DCTH) — RQD Stock Rating Cockpit

$14.29 +1.78% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $14.31

Delcath Systems Inc. (DCTH) carries a Roarable Rating of C- (Hold) with 59/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C- • HOLD / WATCH Cap $487.2M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on DCTH Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is DCTH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Delcath Systems Inc. (NASDAQ: DCTH) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 59/100 at a spot price of $14.29 (+1.78% 1D, market cap $487.2M). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 18/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 11/20. Across 1015 tracked Health Care issuers, DCTH ranks #171 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does DCTH compare to RCEL and SENS in the Health Care sector?
▼

Within the Health Care sector (Medical/Dental Instruments), DCTH carries a Roarable C- (59/100 RQD), trailing P/E of N/A, gross margin of 86.2%, and ROIC of 0.8%. By comparison, RCEL (Avita Medical Inc.) holds a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $484.0M) and SENS (Senseonics Holdings Inc.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $502.8M). Among the 5-stock peer group, DCTH leads on earnings multiple (N/A) while DCTH leads on capital efficiency (0.8% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for DCTH?
▼

Per DCTH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000872912), Delcath Systems Inc. generated $85.2M in revenue (+129.1% YoY), $2.7M in net income, and $21.0M in free cash flow against $123.6M in total assets and $0 in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $14.31 (+0.13%)🧬 Cannibal Buyback (-0.96% YoY Shares)⚙️ Cash Engine: 14/20 (B-) • 24.6% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 59/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.2% avg 90D alpha vs SPY • 53.1% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERHOLD / WATCH • C-
025507510059
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk C+
Cash (14)Whales (7)SEC (18)Macro (9)CEO (11)
Each axis scored 0–20
12M PRICE TARGET CONE+0.4% Base Target
$18 Bull$14 Base$11 Bear
📬 FREE DCTH RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for DCTH)Realized 20D OHLCV Swing Band: ±7.7%
Deterministic 5-Pillar Attribution (59/100 Composite)
🔍 WHY DCTH SCORES 59/100 (C-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+18/20 pts (31% of score)

Altman Z-Score 20.33 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9

▲ #2 Bullish Driver: Cash Engine Quality+14/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 24.6% FCF Margin ($21.0M FCF) & 86.2% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning7/20 pts (-13 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-13 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
67
Grade B-$15.32-3.7% Next Q
Q2 (-2Q)
64
Grade C+$14.76-0.1% Next Q
Q3 (-1Q)
62
Grade C+$14.75-3.1% Next Q
Current
59
Grade C-$14.29+0.2% Hist 90D α
Trajectory: B- (67) → C- (59)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the DCTH Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 59/100 (C-) score, DCTH faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Sensitive to high interest rates and tighter Federal Reserve market liquidity.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-0.96% YoY Shares) — any gross margin slip below 83.7% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($15.56) or 200D SMA ($12.38) invalidates the momentum regime and cuts Target Base ($14.35) toward Bear Floor ($11.19).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $DCTH• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “DCTH Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
RSI-14 MOMENTUMNEUTRAL RANGE
4030 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
20.33>3.0 Fortress Safe
PIOTROSKI F-SCOREHIGH QUALITY (7–9)
8 / 99-Pt Accounting
52-WEEK LASER RANGE66% OF RANGE
L: $8$14.29H: $17
1. Money & Cash Health● MIXED
Are profits real cash in the bank?

Decent core business (86.2% gross margin), though cash flow growth is moderate rather than explosive right now.

Factor Grade: B-RQD 14 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: DRQD 18 / 40
3. Hidden Risks & Market Weather● WATCH
SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: C+RQD 27 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bullish on DCTH

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BULLISH (70)

0.8% ROIC with 86.2% gross margin and 4.13% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BULLISH (90)

Altman-Z 20.33 and Piotroski 8/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (45)

18/40 institutional & smart-money positioning score with 9/20 macro alignment.

Bull Case: Why Buyers Like DCTH
  • ✓Clean SEC annual filing review with no major hidden accounting time-bombs.
Bear Case: What Could Go Wrong
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (DCTH Tape Review)

  • ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
  • ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
DCTH // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +29.67%🛡️ HOLDING TREND SUPPORT
2026-11-03O $14.64H $14.64L $14.04C $14.29VOL 427.4K
RES: $15.16SUP: $13.98SMA50: $15.56SMA200: $12.38
$17.95$15.75$13.54$11.34$9.14RES $15.16SUP $13.98$14.292026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

DCTH Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +129.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on DCTH today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for DCTH. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for DCTH today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (DCTH)

Health Care Rank #171 of 1015 ⚔️ RCEL vs DCTH Full Matrix →

1. Head-to-Head Health Care Peer Comparison (DCTH vs. RCEL, SENS, SSII, ANGO)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Delcath Systems Inc. (DCTH) ranks #171 by composite RQD confidence (59/100, grade C-) and #447 by equity capitalization ($487.2M). Within this direct 5-issuer industry benchmark cohort, DCTH leads on earnings valuation at N/A trailing P/E, while DCTH leads on capital efficiency and profitability with 0.8% ROIC and 86.2% gross margin. DCTH currently leads its immediate peer cohort in composite quantitative strength at 59/100 (C-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
DCTH ACTIVE
Delcath Systems Inc.
C- 59/100 — 86.2% 0.8% +1.78% $487.2M Benchmark Subject
RCEL
Avita Medical Inc.
D 46/100 — 82.1% -35.0% -1.53% $484.0M /rcel-vs-dcth →
SENS
Senseonics Holdings Inc.
D- 40/100 — 44.7% -35.0% -5.57% $502.8M /sens-vs-dcth →
SSII
SS Innovations International Inc.
E 30/100 — 46.0% -18.5% -1.70% $471.1M /ssii-vs-dcth →
ANGO
AngioDynamics Inc.
D- 36/100 — 54.6% -23.4% -1.92% $504.2M /ango-vs-dcth →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000872912 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Delcath Systems Inc. (DCTH) reported GAAP revenue of $85.2M (+129.1% vs. FY2024 revenue of $37.2M , and +4027.4% cumulative change since FY2023) , GAAP net income of $2.7M, operating cash flow of $22.5M, and free cash flow of $21.0M (+209.0% YoY). On the balance sheet, DCTH closed FY2025 with $123.6M in total assets against $0 in total debt (Altman Z-Score: 20.33, Piotroski F-Score: 8/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $85.2M $2.7M $22.5M $21.0M $123.6M —
FY2024 (FY) 2024-12-31 $37.2M -$26.4M -$18.7M -$19.2M $76.6M —
FY2023 (FY) 2023-12-31 $2.1M -$47.7M -$31.3M -$31.3M — —

3. DCTH Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is DCTH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Delcath Systems Inc. (NASDAQ: DCTH) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 59/100 at a spot price of $14.29 (+1.78% 1D, market cap $487.2M). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 18/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 11/20. Across 1015 tracked Health Care issuers, DCTH ranks #171 in composite RQD confidence.

How does DCTH compare to RCEL and SENS in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), DCTH carries a Roarable C- (59/100 RQD), trailing P/E of N/A, gross margin of 86.2%, and ROIC of 0.8%. By comparison, RCEL (Avita Medical Inc.) holds a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $484.0M) and SENS (Senseonics Holdings Inc.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $502.8M). Among the 5-stock peer group, DCTH leads on earnings multiple (N/A) while DCTH leads on capital efficiency (0.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for DCTH?

Per DCTH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000872912), Delcath Systems Inc. generated $85.2M in revenue (+129.1% YoY), $2.7M in net income, and $21.0M in free cash flow against $123.6M in total assets and $0 in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.

Where is DCTH trading relative to its 50-day, 200-day, and 52-week technical levels?

DCTH last traded at $14.29 (+1.78% on volume of 364,906 shares), positioning the stock -8.16% below its 50-day simple moving average ($15.56) and +15.43% above its 200-day simple moving average ($12.38). Across its 52-week range of $8.12 to $17.42, DCTH sits at the 66.3% percentile with a 14-day RSI of 40.0 (NEUTRAL RANGE) and an implied next-earnings move of ±7.7% ($13.19 to $15.39).

ROARABLE RATING BRIEF • RQD 59/100 (C-) ✓ SEC XBRL & RQD VERIFIED

DCTH — Delcath Systems Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Delcath Systems Inc. (DCTH) earns a live Roarable RQD composite score of 59/100, corresponding to a C- letter grade (Roarable Hold) at a spot price of $14.29 (+1.78% 1D, market capitalization $487.2M).

  • Fundamental Cash Engine (14/20): Anchored by return on invested capital (ROIC) of 0.8%, gross margin of 86.2%, operating margin of 0.8%, and free cash flow yield of 4.13%.
  • Whale 13F & Options Flow (7/20) + Insider Conviction (11/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (9/20) + Forensic Balance Sheet (18/20): Incorporates a 1.00x equity beta, Altman Z-Score of 20.33, Piotroski F-Score of 8/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Delcath Systems Inc. (DCTH) is a NASDAQ-listed issuer in the Health Care sector, within the Medical/Dental Instruments industry. The profile identifies the company as operating in this sector and industry with a market capitalization of $0.5B. Reported revenue grew from $2.1M in FY 2023 to $37.2M in FY 2024 and $85.2M in FY 2025.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Delcath Systems Inc. (DCTH) reported $85.2M in annual revenue (up from $37.2M in FY2024, +129.1% YoY) and $2.7M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($2.1M revenue, -$47.7M net income) through FY2025, DCTH scaled operating cash flow to $22.5M and free cash flow to $21.0M, backed by $123.6M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (C- • RQD 59/100): Clean SEC annual filing review with no major hidden accounting time-bombs. Free cash flow yield of 4.13% and institutional whale pillar of 7/20. With Fundamental Cash Engine at 14/20 and Institutional Whale Flow at 7/20, sustained execution supports upside toward the upper end of the $8.12 – $17.42 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Investors must weigh current valuation against 0.8% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

— The Butterfly Supply-Chain Graph lists no upstream or downstream links and no sector correlations. Investors should note that the dossier therefore cannot map supplier, customer, or competitor dependencies from the provided sources.

  • Key Question #1: Can DCTH sustain or expand its 0.8% operating margin and 0.8% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $85.2M and free cash flow of $21.0M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is DCTH's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

DCTH Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Delcath Systems Inc. (DCTH) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to DCTH Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

DCTH Bull vs. Bear Conversation Board — What's Your Call at $14.29?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON DCTH 🐻 33% BEARISH CONVICTION
1. Pick Your Side on DCTH:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $17.41 (+24.0%)
📌 Pinned Debate

Revenue scaled from $2.1M in FY 2023 to $85.2M in FY 2025 with FY 2025 FCF of $21.0M, and the forensic balance sheet scores 18 of 20.

Here is why I am bullish on DCTH here at $14.04: Revenue scaled from $2.1M in FY 2023 to $85.2M in FY 2025 with FY 2025 FCF of $21.0M, and the forensic balance sheet scores 18 of 20.. Compare DCTH's 0.8% operating margin and 0.8% ROIC against the rest of Medical/Dental Instruments. As long as cash conversion holds up, dips toward $13.34 are getting bought.

CapAlloc_Nerd 🐂 BULL

@QuantViper Agree on the RQD 59/100 quality, though with 1.0 beta I'm scaling in with half-size at $14.04 and keeping dry powder in case we test $13.06.

FO ForensicBear RQD DEBATE OPENER • 10-K Footnote Auditor 🐻 BEARISH 🎯 Target: $10.67 (-24.0%)
Spot @ $14.04

ROIC is only 0.8% and operating margin is 0.8%, with macro regime fit scoring 9 of 20 and no earnings multiples available to justify va

ROIC is only 0.8% and operating margin is 0.8%, with macro regime fit scoring 9 of 20 and no earnings multiples available to justify valuation.. Look at the math on DCTH: paying current EV/EBITDA multiples for 0.8% ROIC and 0.8% operating margins leaves zero margin of safety if Medical/Dental Instruments demand softens. I'd wait for a retest of $12.36 before getting long.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%